Carcinoid syndrome laboratory tests: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(9 intermediate revisions by 2 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
Laboratory findings consistent with the diagnosis of carcinoid syndrome include an elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) and plasma levels of Chromogranin A (CgA) levels.<ref name=diagnostics>Diagnostics: Biochemical Markers, Imaging, and Approach. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq</ref>
Laboratory findings consistent with the diagnosis of [[Carcinoid Syndrome|carcinoid syndrome]] include an elevated [[urinary]] [[5-hydroxyindoleacetic acid]] (5-HIAA) and [[Plasma (blood)|plasma]] levels of [[Chromogranin A]] (CgA) levels.[[N-terminal pro–B-type natriuretic peptide]] is a useful [[Biomarker (cell)|biomarker]] of [[carcinoid]] [[heart]] [[disease]].


==Laboratory Findings==
==Laboratory Findings==
*Laboratory findings consistent with the diagnosis of carcinoid syndrome include an elevated urinary [[5-hydroxyindoleacetic acid]] (5-HIAA) and plasma levels of Chromogranin A (CgA) levels.<ref name=diagnostics>Diagnostics: Biochemical Markers, Imaging, and Approach. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq</ref>
*[[Urinary]] [[5-hydroxyindoleacetic acid]] (5-HIAA) are elevated and [[Plasma (blood)|plasma]] levels of [[Chromogranin A]] (CgA) levels.<ref name="diagnostics">Diagnostics: Biochemical Markers, Imaging, and Approach. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq</ref>
*Testing for elevated urinary [[5-hydroxyindoleacetic acid]] (5-HIAA) has a specificity of approximately 88%, although the sensitivity is reported to be as low as 35%.
*Testing for elevated [[urinary]] [[5-hydroxyindoleacetic acid]] (5-HIAA) has a specificity of approximately 88%, although the [[sensitivity]] is reported to be as low as 35%.
*Plasma levels of Chromogranin A (CgA) are very sensitive markers of carcinoid syndrome, but not specific as they are also elevated in other types of neuroendocrinal tumors such as [[pancreatic]] and [[lung carcinoma|small cell lung carcinomas]].
*[[Plasma (blood)|Plasma levels]] of [[Chromogranin A]] (CgA) are very sensitive markers of [[Carcinoid Syndrome|carcinoid syndrome]], but not specific as they are also elevated in other types of [[Neuroendocrine tumor|neuroendocrinae tumors]] such as [[pancreatic]] and [[lung carcinoma|small cell lung carcinomas]].
*Other biochemical markers associated with carcinoid syndrome include:<ref name=diagnostics>Diagnostics: Biochemical Markers, Imaging, and Approach. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq</ref>
*[[N-terminal pro–B-type natriuretic peptide]] : It is a useful biomarker of [[Carcinoid disease|carcinoid heart disease]] at a cutoff level of 260 pg/ml (31 pmol/l).<ref name="pmid24069222">{{cite journal |vauthors=Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, Wong C, Chadwick C, George K, Keevil B, Adaway J, Ardill JE, Anthoney A, Hofmann U, Poston GJ, Cuthbertson DJ |title=The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study |journal=PLoS ONE |volume=8 |issue=9 |pages=e73679 |date=2013 |pmid=24069222 |pmc=3771983 |doi=10.1371/journal.pone.0073679 |url=}}</ref>
*N-terminal pro–B-type natriuretic peptide used as a [[screening]] tool for [[Carcinoid|carcinoid heart disease i]]<nowiki/>n patients with [[Carcinoid Syndrome|carcinoid syndrome]].<ref name="pmid18805126">{{cite journal |vauthors=Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J |title=Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease |journal=Am. J. Cardiol. |volume=102 |issue=7 |pages=938–42 |date=October 2008 |pmid=18805126 |doi=10.1016/j.amjcard.2008.05.047 |url=}}</ref>
*Other biochemical markers associated with [[Carcinoid Syndrome|carcinoid syndrome]] include:<ref name="diagnostics">Diagnostics: Biochemical Markers, Imaging, and Approach. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq</ref>
**[[Substance P]]
**[[Substance P]]
**[[Neurotensin]]
**[[Neurotensin]]
**[[Bradykinin]]
**[[Bradykinin]]
**[[Human chorionic gonadotropin]]
**[[Human chorionic gonadotropin]]
**Neuropeptide L
**[[Neuropeptide]] L
**[[Pancreatic polypeptide]]
**[[Pancreatic polypeptide]]


Line 27: Line 29:
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Gastroenterology]]
[[Category:Endocrinology]]
[[Category:Surgery]]

Latest revision as of 15:06, 25 April 2019

Carcinoid syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Carcinoid Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carcinoid syndrome laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Carcinoid syndrome laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carcinoid syndrome laboratory tests

CDC on Carcinoid syndrome laboratory tests

Carcinoid syndrome laboratory tests in the news

Blogs on Carcinoid syndrome laboratory tests

Directions to Hospitals Treating Carcinoid syndrome

Risk calculators and risk factors for Carcinoid syndrome laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Laboratory findings consistent with the diagnosis of carcinoid syndrome include an elevated urinary 5-hydroxyindoleacetic acid (5-HIAA) and plasma levels of Chromogranin A (CgA) levels.N-terminal pro–B-type natriuretic peptide is a useful biomarker of carcinoid heart disease.

Laboratory Findings

References

  1. 1.0 1.1 Diagnostics: Biochemical Markers, Imaging, and Approach. National cancer institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq
  2. Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, Wong C, Chadwick C, George K, Keevil B, Adaway J, Ardill JE, Anthoney A, Hofmann U, Poston GJ, Cuthbertson DJ (2013). "The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study". PLoS ONE. 8 (9): e73679. doi:10.1371/journal.pone.0073679. PMC 3771983. PMID 24069222.
  3. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J (October 2008). "Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease". Am. J. Cardiol. 102 (7): 938–42. doi:10.1016/j.amjcard.2008.05.047. PMID 18805126.

Template:WS Template:WH